Tesla is working on new battery cell designs, and a way to make their own cells, with R&D teams in a lab near its car plant in Fremont, California.Technologyread more
The Federal Reserve and the market are miles apart on interest rate expectations, and the disparity could cost the stock market a 7%-10% drop, economists say.Economyread more
President Trump lambastes Twitter, Google and other technology giants for what he claims as their efforts to stifle him.US Economyread more
Underneath the impressive market rally is a trend that doesn't seem quite right, according to J.P. Morgan.Marketsread more
The shutdown of the fire-damaged Philadelphia Energy Solutions refining complex could send gasoline prices higher across the U.S., but particularly in the mid-Atlantic region...Market Insiderread more
Mnuchin tells CNBC he's confident President Trump and China's Xi Jinping can make progress in stalled trade talks.World Economyread more
Bitcoin topped the $13,000 level Wednesday, rallying to its highest price since January 2018.Bitcoinread more
JP Morgan's Jamie Dimon says student lending "is a disgrace and it's hurting America."Economyread more
During the foreclosure crisis, investors transformed the single-family home rental market into a formally managed asset class. Now they want new homes.Real Estateread more
Wayfair drew backlash and calls from some customers for a boycott after employees protested the company's apparent sale of $200,000 of mattresses and bunk beds destined for a...Retailread more
These are the stocks posting the largest moves midday.Market Insiderread more
Idorsia founder and CEO Jean-Paul Clozel said his biotech group has the resources to assess trial data and decide what to do with assets, as spending on projects led to a 386 million Swiss franc ($385 million) loss in 2018.
The Swiss company still has total liquidity of 1.22 billion francs, down from 1.35 billion francs on Sept. 30.
Clozel, who spun Idorsia out of Actelion after that drugmaker's $30 billion sale in 2017 to Johnson & Johnson, last year initiated four late-stage trials of medicines, including against insomnia, brain bleeding, resistant hypertension and rare Fabry Disease.
Clozel, who said Idorsia "cut the umbilical cord" from Actelion over the course of 2018, sees operating expenses of around 570 million francs in the current year, up from 432 million last year, as trials on these and other molecules advance.
"The level of financing required for a diversified drug pipeline can pose certain challenges for a young company," Clozel said in a statement. "The 505 million francs raised in July 2018 should give us the necessary leeway to assess the clinical data for our late-stage pipeline and then make the appropriate strategic decisions regarding commercialisation."